IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
Relative valuation derived from Healthcare sector median benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Multiples adjusted for extreme outliers and non-recurring volatility.
Auditing capital efficiency...
Quality Profile Audit
Score: 50GRADE C+
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation.
Return on Equity
Profit generated per dollar of shareholder equity
18.0%
Sector: -43.5%
Dividend Analysis audit
No Dividend
This company does not currently pay a dividend.
Analyst Projections
Analyst Consensus
Unlock Valuation Tools
Sign up for free access to institutional-quality research tools.
Based on our 6-factor quantitative model, UNITED THERAPEUTICS Corp (UTHR) receives a "Hold" rating with a composite score of 51.4/100, ranked #271 out of 4446 stocks. Key factor scores: Quality 50/100, Value 63/100, Momentum 66/100. This is quantitative analysis only — not investment advice.
UNITED THERAPEUTICS Corp (UTHR) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does UNITED THERAPEUTICS Corp Do?
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. UNITED THERAPEUTICS Corp (UTHR) is classified as a large-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Martine A. Rothblatt and employs approximately 980 people, headquartered in SILVER SPRING, Maryland. With a market capitalization of $25.0B, UTHR is one of the prominent companies in the Healthcare sector.
UNITED THERAPEUTICS Corp (UTHR) Stock Rating — Hold (April 2026)
As of April 2026, UNITED THERAPEUTICS Corp receives a Hold rating with a composite score of 51.4/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.UTHR ranks #271 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, UNITED THERAPEUTICS Corp ranks #7 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
UTHR Stock Price and 52-Week Range
UNITED THERAPEUTICS Corp (UTHR) currently trades at $567.78. The stock lost $6.99 (1.2%) in the most recent trading session. The 52-week high for UTHR is $548.12, which means the stock is currently trading 3.6% from its annual peak. The 52-week low is $266.98, putting the stock 112.7% above its annual trough. Recent trading volume was 186K shares, suggesting relatively thin trading activity.
Is UTHR Overvalued or Undervalued? — Valuation Analysis
UNITED THERAPEUTICS Corp (UTHR) carries a value factor score of 63/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 19.38x, compared to the Healthcare sector average of 23.63x — a discount of 18%. The price-to-book ratio stands at 3.49x, versus the sector average of 2.75x. The price-to-sales ratio is 7.89x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, UTHR trades at 16.45x EV/EBITDA, versus 6.34x for the sector. The EV/EBIT multiple is 11.27x.
Overall, UTHR's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
UNITED THERAPEUTICS Corp Profitability — ROE, Margins, and Quality Score
UNITED THERAPEUTICS Corp (UTHR) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 18.0%, compared to the Healthcare sector average of -43.5%, which is within a healthy range. Return on assets (ROA) comes in at 16.2% versus the sector average of -33.1%.
On a margin basis, UNITED THERAPEUTICS Corp reports gross margins of 88.4%, compared to 71.5% for the sector. The operating margin is 47.1% (sector: -66.1%). Net profit margin stands at 40.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 11.8% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.
UTHR Debt, Balance Sheet, and Financial Health
UNITED THERAPEUTICS Corp has a debt-to-equity ratio of 11.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 6.60x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $1.34B.
UTHR has a beta of 0.58, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for UNITED THERAPEUTICS Corp is 62/100, reflecting average volatility within the normal range for its sector.
UNITED THERAPEUTICS Corp Revenue and Earnings History — Quarterly Trend
In TTM 2026, UNITED THERAPEUTICS Corp reported revenue of $3.14B and earnings per share (EPS) of $30.13. Net income for the quarter was $1.28B. Gross margin was 88.4%. Operating income came in at $1.48B.
In FY 2025, UNITED THERAPEUTICS Corp reported revenue of $3.18B and earnings per share (EPS) of $30.13. Net income for the quarter was $1.33B. Gross margin was 87.9%. Revenue grew 10.6% year-over-year compared to FY 2024. Operating income came in at $1.49B.
In Q3 2025, UNITED THERAPEUTICS Corp reported revenue of $800M and earnings per share (EPS) of $7.73. Net income for the quarter was $339M. Gross margin was 87.4%. Revenue grew 6.8% year-over-year compared to Q3 2024. Operating income came in at $389M.
In Q2 2025, UNITED THERAPEUTICS Corp reported revenue of $799M and earnings per share (EPS) of $6.86. Net income for the quarter was $310M. Gross margin was 89.0%. Revenue grew 11.7% year-over-year compared to Q2 2024. Operating income came in at $365M.
Over the past 8 quarters, UNITED THERAPEUTICS Corp has demonstrated a growth trajectory, with revenue expanding from $715M to $3.14B. Investors analyzing UTHR stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
UTHR Dividend Yield and Income Analysis
UNITED THERAPEUTICS Corp (UTHR) does not currently pay a dividend. This is common among growth-oriented companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
UTHR Momentum and Technical Analysis Profile
UNITED THERAPEUTICS Corp (UTHR) has a momentum factor score of 66/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 28/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 15/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
UTHR vs Competitors — Healthcare Sector Ranking and Peer Comparison
Comparing UTHR against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full UTHR vs S&P 500 (SPY) comparison to assess how UNITED THERAPEUTICS Corp stacks up against the broader market across all factor dimensions.
UTHR Next Earnings Date
No upcoming earnings date has been announced for UNITED THERAPEUTICS Corp (UTHR) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy UTHR? — Investment Thesis Summary
UNITED THERAPEUTICS Corp presents a balanced picture with arguments on both sides. The value score of 63/100 suggests attractive pricing relative to fundamentals. Price momentum is positive at 66/100, suggesting the trend favors buyers. Low volatility (stability score 62/100) reduces downside risk.
In summary, UNITED THERAPEUTICS Corp (UTHR) earns a Hold rating with a composite score of 51.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on UTHR stock.
We'll email you when stocks you follow change their composite rating.
Institutional Research Dossier
UNITED THERAPEUTICS Corp (UTHR) Deep Dive Analysis
Published on March 24, 2026
Action RatingHold
Sections
Executive Summary
United Therapeutics (UTHR) receives a Hold rating, reflecting a balanced view of its strong profitability and growth prospects against potential risks associated with its concentrated product portfolio and reliance on regulatory approvals. While the company exhibits impressive financial metrics and a dominant position in the pulmonary hypertension (PH) market, uncertainties surrounding future pipeline developments and competitive pressures warrant a cautious approach. The key takeaway is that UTHR's current valuation appears fair, considering its growth trajectory and inherent risks, suggesting limited upside potential in the near term.
The company's robust financial performance, characterized by high margins and substantial cash flow, is undeniably attractive. However, the dependence on a relatively small number of key products exposes UTHR to significant downside risk if these products face patent expirations or increased competition. Therefore, while UTHR presents a compelling investment case based on its current performance, a Hold rating is justified until greater clarity emerges regarding its long-term growth strategy and ability to diversify its revenue streams.
Business Strategy & Overview
United Therapeutics Corporation operates as a biotechnology company focused on developing and commercializing therapies for chronic and life-threatening diseases, primarily in the field of pulmonary hypertension (PH). The company's revenue is largely derived from its portfolio of PAH treatments, including Remodulin, Tyvaso, Orenitram, and Adcirca. Unituxin, used to treat high-risk neuroblastoma, contributes a smaller portion of overall revenue. The core strategy revolves around maximizing the commercial potential of its existing product line while simultaneously investing in research and development to expand its pipeline and address unmet medical needs in related therapeutic areas.
A key element of UTHR's strategy is the development of innovative drug delivery systems and formulations to improve patient outcomes and extend the lifecycle of its existing products. Examples include Tyvaso DPI, a dry powder inhalation formulation of Tyvaso, and the Remunity Pump, a next-generation subcutaneous delivery system for treprostinil. These initiatives aim to enhance patient convenience, improve drug efficacy, and maintain market share in the face of generic competition. Furthermore, the company is actively pursuing clinical trials to expand the indications for its existing drugs, such as the Tyvaso PERFECT and TETON studies, which are evaluating Tyvaso in patients with PH-COPD.
United Therapeutics also employs a strategy of strategic collaborations and licensing agreements to access external innovation and accelerate the development of new therapies. The company has partnerships with DEKA Research & Development Corp., MannKind Corporation, and Arena Pharmaceuticals, Inc. to develop novel drug delivery systems and therapeutic candidates. These collaborations allow UTHR to leverage external expertise and resources to complement its internal R&D efforts and broaden its pipeline.
The competitive landscape for UTHR is characterized by the presence of both established pharmaceutical companies and emerging biotechnology firms. Key competitors in the PAH market include companies offering alternative prostacyclin analogs, PDE-5 inhibitors, and endothelin receptor antagonists. UTHR differentiates itself through its focus on innovative drug delivery systems, its comprehensive product portfolio, and its commitment to addressing unmet medical needs in the PH space. The company's long-term success hinges on its ability to maintain its competitive advantage through continued innovation, strategic collaborations, and effective commercial execution.
Execution Benchmarks audit
Revenue Growth
YOY expansion rate
11.8%
Sector: 10.6%
+11% VS SCTR
Economic Moat Analysis
United Therapeutics possesses a narrow economic moat, primarily derived from intangible assets in the form of patents and regulatory exclusivity surrounding its key products, particularly in the treatment of pulmonary hypertension (PH). While the company has successfully developed and commercialized several leading therapies in this niche market, the durability of its competitive advantage is subject to ongoing challenges.
The patent protection afforded to UTHR's drugs provides a period of market exclusivity, allowing the company to generate substantial profits without direct generic competition. However, these patents eventually expire, opening the door for generic manufacturers to enter the market and erode UTHR's market share. The company's strategy of developing new formulations and delivery systems, such as Tyvaso DPI and the Remunity Pump, aims to extend the lifecycle of its existing products and maintain a competitive edge. However, the success of these initiatives is not guaranteed, and competitors may develop alternative strategies to circumvent UTHR's intellectual property.
Regulatory exclusivity, such as orphan drug designation, also contributes to UTHR's moat by providing additional protection from competition. However, this exclusivity is typically limited in duration and scope. Furthermore, the regulatory landscape for pharmaceuticals is constantly evolving, and changes in regulations could impact UTHR's ability to maintain its competitive advantage.
While UTHR has established a strong brand reputation and a loyal customer base within the PH community, these factors alone are not sufficient to create a wide economic moat. The company's reliance on a relatively small number of key products exposes it to significant downside risk if these products face patent expirations, regulatory challenges, or increased competition. Therefore, while UTHR's intangible assets provide a temporary competitive advantage, the company's moat is considered narrow due to the limited durability of these advantages and the potential for disruption from competitors.
The absence of network effects or significant switching costs further limits the strength of UTHR's moat. Patients can readily switch to alternative therapies if they offer comparable efficacy and safety profiles, and there are no significant barriers to entry for new competitors with innovative products. Consequently, UTHR must continuously invest in research and development to maintain its competitive position and defend its market share.
Financial Health & Profitability
United Therapeutics exhibits strong financial health, characterized by robust revenue growth, high margins, and substantial cash flow generation. The company's revenue has consistently increased over the past several years, driven by the strong performance of its PAH therapies. The TTM revenue of $3.18 billion represents an 11.8% increase compared to the sector average of 10.7%. This growth trajectory is further evidenced by the quarterly financial history, which shows a steady increase in revenue from $506.90 million in Q1 2023 to $799.50 million in Q3 FY2025.
UTHR's profitability metrics are also impressive, with a gross margin of 88.4% and an operating margin of 47.1%. These margins significantly exceed the sector averages of 71.9% and -65.2%, respectively, indicating UTHR's ability to efficiently manage its costs and generate substantial profits from its operations. The company's net income of $1.33 billion translates to a net margin of 40.7%, further highlighting its strong profitability.
The balance sheet is exceptionally strong, with $1.34 billion in total cash and no debt. This provides UTHR with significant financial flexibility to invest in research and development, pursue strategic acquisitions, and return capital to shareholders. The current ratio of 6.60 indicates a high level of liquidity, suggesting that UTHR has ample resources to meet its short-term obligations.
UTHR's return on equity (ROE) of 18.0% is significantly higher than the sector average of -42.5%, demonstrating the company's ability to generate attractive returns on its shareholders' equity. The company's free cash flow (FCF) of $764.78 million further underscores its strong cash flow generation capabilities. However, the quarterly FCF data is incomplete, limiting the ability to analyze trends in FCF generation over time.
Overall, United Therapeutics' financial health is exceptionally strong, characterized by robust revenue growth, high margins, a pristine balance sheet, and strong cash flow generation. This financial strength provides UTHR with a solid foundation for future growth and value creation.
Valuation Assessment
United Therapeutics' valuation presents a mixed picture, suggesting that the stock is currently fairly valued. The company's P/E ratio of 17.4x is lower than the sector average of 24.3x, indicating that UTHR may be undervalued relative to its peers. However, this comparison should be interpreted with caution, as the healthcare sector includes a wide range of companies with varying growth prospects and risk profiles.
The EV/EBITDA ratio of 3.9x is also significantly lower than the sector average of 6.4x, further suggesting that UTHR may be undervalued. This metric compares the company's enterprise value (market capitalization plus debt minus cash) to its earnings before interest, taxes, depreciation, and amortization, providing a more comprehensive measure of valuation than the P/E ratio.
However, it's crucial to consider UTHR's growth prospects when assessing its valuation. The company's revenue growth of 11.8% is slightly higher than the sector average of 10.7%, indicating that UTHR is growing at a faster pace than its peers. This growth justifies a higher valuation multiple. Furthermore, UTHR's high margins and strong cash flow generation support a premium valuation.
Considering the company's strong financial performance, growth prospects, and inherent risks, the current valuation appears to be fair. While the P/E and EV/EBITDA ratios suggest that UTHR may be undervalued, these metrics do not fully capture the company's unique characteristics and growth potential. A more comprehensive valuation analysis, incorporating discounted cash flow (DCF) modeling and sensitivity analysis, would be required to determine a more precise fair value estimate. However, based on the available data, the stock appears to be trading at a reasonable price, reflecting its growth trajectory and inherent risks.
The BCR proprietary quant model assigns a Value score of 65/100, suggesting that the stock is moderately undervalued based on its multiples. However, the overall Composite Score of 50.9/100 and the Hold rating indicate that the model does not view the stock as a compelling investment opportunity at its current price.
Risk & Uncertainty
United Therapeutics faces several specific, idiosyncratic risks that could negatively impact its business and financial performance. A primary risk is the concentration of revenue within a limited number of key products, particularly those targeting pulmonary hypertension (PH). Any adverse event affecting these products, such as patent expirations, regulatory setbacks, or the emergence of superior competing therapies, could significantly reduce UTHR's revenue and profitability.
Regulatory risk is also a significant concern for UTHR. The company's products are subject to extensive regulatory oversight by the FDA and other regulatory agencies. Changes in regulations, delays in regulatory approvals, or adverse regulatory actions could negatively impact UTHR's ability to commercialize its products and maintain its market share. The ongoing clinical trials for expanded indications of Tyvaso, such as the PERFECT and TETON studies, are subject to regulatory approval, and any delays or rejections could impact the company's growth prospects.
Competition in the PH market is intense, with several established pharmaceutical companies and emerging biotechnology firms vying for market share. The development of new and improved therapies by competitors could erode UTHR's market position and reduce its pricing power. The company's ability to maintain its competitive advantage depends on its continued investment in research and development and its ability to successfully commercialize innovative products.
Another risk is related to the company's reliance on strategic collaborations and licensing agreements. These agreements are subject to various risks, including the failure of partners to fulfill their obligations, disputes over intellectual property rights, and the termination of agreements. Any adverse event affecting these collaborations could negatively impact UTHR's ability to develop and commercialize new therapies.
Bulls Say / Bears Say
The Bull Case
BULL VIEWUnited Therapeutics' strong financial performance and dominant position in the pulmonary hypertension market make it a compelling investment opportunity.
BULL VIEWThe company's innovative drug delivery systems and pipeline of new therapies position it for continued growth and market leadership.
BULL VIEWUTHR's pristine balance sheet and strong cash flow generation provide ample financial flexibility for strategic acquisitions and shareholder returns.
The Bear Case
BEAR VIEWUnited Therapeutics' reliance on a limited number of key products exposes it to significant downside risk from patent expirations and competition.
BEAR VIEWThe company's high valuation and dependence on regulatory approvals make it vulnerable to market corrections and regulatory setbacks.
BEAR VIEWUTHR's lack of a wide economic moat and limited diversification raise concerns about its long-term sustainability and competitive advantage.
About the Author
Marques Blank
Founder & Chief Investment Officer, Blank Capital
Marques brings 15 years of institutional finance and investing experience, having overseen financial planning for a $1.6B defense business unit. He developed the proprietary 6-factor quantitative model used to score UTHR and 4,400+ other equities.
UNITED THERAPEUTICS Corp exhibits a 136% valuation premium relative to institutional benchmarks. This represents a potential valuation overextension based on current multiples.
Return on Assets
Efficiency of asset utilization
16.2%
Sector: -33.1%
Gross Margin
Pricing power and cost efficiency
88.4%
Sector: 71.5%
Operating Margin
Core business profitability
47.1%
Sector: -66.1%
Net Margin
Bottom-line profitability
40.7%
Sector: -58.7%
Factor Methodology
The Quality factor evaluates the persistence and magnitude of cash flows. Companies with scores >70 exhibit superior competitive moats and financial resilience through economic cycles.
